BidaskClub cut shares of Ionis Pharmaceuticals (NASDAQ:IONS) from a buy rating to a hold rating in a research report released on Friday morning.

Other equities research analysts have also issued reports about the stock. Needham & Company LLC reaffirmed a buy rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. BMO Capital Markets reaffirmed an outperform rating and set a $69.00 price target on shares of Ionis Pharmaceuticals in a report on Monday, October 2nd. Barclays lowered their price target on shares of Ionis Pharmaceuticals from $55.00 to $52.00 and set an equal weight rating for the company in a report on Thursday, September 21st. Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, November 9th. Finally, Goldman Sachs Group reaffirmed a sell rating and set a $30.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, October 6th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company’s stock. Ionis Pharmaceuticals presently has an average rating of Hold and an average target price of $50.31.

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) opened at $50.86 on Friday. Ionis Pharmaceuticals has a 52-week low of $37.26 and a 52-week high of $65.51. The stock has a market cap of $6,320.00, a price-to-earnings ratio of 363.29 and a beta of 2.85. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50.

In other news, Chairman Stanley T. Crooke sold 27,500 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $52.89, for a total value of $1,454,475.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Stanley T. Crooke sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $52.00, for a total transaction of $780,000.00. Following the completion of the transaction, the chief executive officer now owns 43,014 shares in the company, valued at $2,236,728. The disclosure for this sale can be found here. Over the last three months, insiders have sold 131,886 shares of company stock valued at $7,516,135. 2.13% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of IONS. Vanguard Group Inc. increased its stake in Ionis Pharmaceuticals by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock valued at $501,332,000 after buying an additional 417,364 shares during the period. BlackRock Inc. increased its stake in Ionis Pharmaceuticals by 4.0% during the 2nd quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock valued at $347,135,000 after buying an additional 264,179 shares during the period. American Century Companies Inc. increased its stake in Ionis Pharmaceuticals by 33.0% during the 3rd quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock valued at $58,027,000 after buying an additional 284,266 shares during the period. First Trust Advisors LP increased its stake in Ionis Pharmaceuticals by 40.2% during the 3rd quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock valued at $49,805,000 after buying an additional 281,733 shares during the period. Finally, Northern Trust Corp increased its stake in Ionis Pharmaceuticals by 7.8% during the 2nd quarter. Northern Trust Corp now owns 621,816 shares of the company’s stock valued at $31,631,000 after buying an additional 44,750 shares during the period. Institutional investors own 91.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Ionis Pharmaceuticals (IONS) Downgraded by BidaskClub” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://theolympiareport.com/2017/12/25/ionis-pharmaceuticals-ions-downgraded-by-bidaskclub.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.